Bedaquilina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bedaquilina" in Italian language version.

refsWebsite

Global rank Italian rank

18doi.org

2^nd place

7^th place

13nih.gov

4^th place

9^th place

6web.archive.org

1^st place

6oadoi.org

799^th place

22^nd place

5worldcat.org

5^th place

26^th place

5unibo.it

4,963^rd place

325^th place

2europa.eu

68^th place

57^th place

2harvard.edu

18^th place

104^th place

2informazionisuifarmaci.it

low place

2torrinomedica.it

low place

2,002^nd place

1researchgate.net

120^th place

267^th place

1vu.nl

8,540^th place

low place

1stolaf.edu

low place

1wsj.com

79^th place

214^th place

1ctvnews.ca

768^th place

1,384^th place

1nytimes.com

7^th place

19^th place

1who.int

195^th place

342^nd place

1gazzettaufficiale.it

2,836^th place

107^th place

1fda.gov

447^th place

644^th place

1msfaccess.org

low place

ctvnews.ca

U.S. FDA approves first new tuberculosis drug in 40 years, su ctvnews.ca. URL consultato il 21 gennaio 2021.

doi.org

dx.doi.org

Anil Koul, Najoua Dendouga, Karen Vergauwen, Brenda Molenberghs, Luc Vranckx, Rudy Willebrords, Zorica Ristic, Holger Lill, Ismet Dorange, Jerome Guillemont, Dirk Bald e Koen Andries, Diarylquinolines target subunit c of mycobacterial ATP synthase, in Nature Chemical Biology, vol. 3, n. 6, 2007, pp. 323-324, DOI:10.1038/nchembio884, ISSN 1552-4450 (WC · ACNP), PMID 17496888.
A. C. Haagsma, R. Abdillahi-Ibrahim, M. J. Wagner, K. Krab, K. Vergauwen, J. Guillemont, K. Andries, H. Lill, A. Koul e D. Bald, Selectivity of TMC207 towards Mycobacterial ATP Synthase Compared with That towards the Eukaryotic Homologue (PDF), in Antimicrobial Agents and Chemotherapy, vol. 53, n. 3, 2008, pp. 1290-2, DOI:10.1128/AAC.01393-08, PMC 2650532, PMID 19075053.
Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis., in Lancet Respir Med, 2017, DOI:10.1016/S2213-2600(17)30079-6, PMID 28344011.
Keam SJ, Pretomanid: First Approval., in Drugs, vol. 79, n. 16, 2019, pp. 1797-1803, DOI:10.1007/s40265-019-01207-9, PMID 31583606.
Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy CA, In search of new cures for tuberculosis (PDF), in Medicinal Chemistry, vol. 3, n. 3, maggio 2007, pp. 301-16, DOI:10.2174/157340607780620626, PMID 17504204. URL consultato il 21 gennaio 2021 (archiviato dall'url originale il 3 luglio 2020).
de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K, A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910, in Proteins, vol. 67, n. 4, giugno 2007, pp. 971-80, DOI:10.1002/prot.21376, PMID 17387738.
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Treatment of Highly Drug-Resistant Pulmonary Tuberculosis., in N Engl J Med, vol. 382, n. 10, 2020, pp. 893-902, DOI:10.1056/NEJMoa1901814, PMC 6955640, PMID 32130813.
Worley MV, Estrada SJ, Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis, in Pharmacotherapy, vol. 34, n. 11, novembre 2014, pp. 1187-97, DOI:10.1002/phar.1482, PMC 5028565, PMID 25203970.
Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A, Acquired resistance of Mycobacterium tuberculosis to bedaquiline, in PLOS ONE, vol. 9, n. 7, 10 luglio 2014, pp. e102135, Bibcode:2014PLoSO...9j2135A, DOI:10.1371/journal.pone.0102135, PMC 4092087, PMID 25010492.
Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, Schulz M, Lu P, Mørtz E, McKinney JD, Andries K, Bald D, Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism, in Nature Communications, vol. 5, n. 1, febbraio 2014, p. 3369, Bibcode:2014NatCo...5.3369K, DOI:10.1038/ncomms4369, PMC 3948051, PMID 24569628.
(EN) Elin Svensson et al., Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children, in Br J Clin Pharmacol., vol. 84, n. 10, ottobre 2018, pp. 2384-2392, DOI:10.1111/bcp.13696. URL consultato il 14 gennaio 2021 (archiviato dall'url originale il 20 gennaio 2022).
Healan AM, Griffiss JM, Proskin HM, O'Riordan MA, Gray WA, Salata RA, Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers., in Antimicrob Agents Chemother, vol. 62, n. 1, 2018, DOI:10.1128/AAC.00855-17, PMC 5740348, PMID 29061739.
Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F, Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB., in J Antimicrob Chemother, vol. 71, n. 4, 2016, pp. 1037-40, DOI:10.1093/jac/dkv447, PMID 26747099.
Emanuele Pontali, Giovanni Sotgiu, Simon Tiberi, Lia D'Ambrosio, Rosella Centis e Giovanni B. Migliori, Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence, in European Respiratory Journal, vol. 50, n. 5, 2017, p. 1701462, DOI:10.1183/13993003.01462-2017, ISSN 0903-1936 (WC · ACNP).
Edward Cox e Katherine Laessig, FDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant Tuberculosis, in New England Journal of Medicine, vol. 371, n. 8, 2014, pp. 689-691, DOI:10.1056/NEJMp1314385, ISSN 0028-4793 (WC · ACNP).
Andreas H. Diacon, Alexander Pym, Martin P. Grobusch, Jorge M. de los Rios, Eduardo Gotuzzo, Irina Vasilyeva, Vaira Leimane, Koen Andries, Nyasha Bakare, Tine De Marez, Myriam Haxaire-Theeuwes, Nacer Lounis, Paul Meyvisch, Els De Paepe, Rolf P.G. van Heeswijk e Brian Dannemann, Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline, in New England Journal of Medicine, vol. 371, n. 8, 2014, pp. 723-732, DOI:10.1056/NEJMoa1313865, ISSN 0028-4793 (WC · ACNP).
Karen Cohen e Gary Maartens, A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis, in Expert Opinion on Drug Safety, vol. 18, n. 10, 2019, pp. 875-882, DOI:10.1080/14740338.2019.1648429, ISSN 1474-0338 (WC · ACNP).
Salinger DH, Nedelman JR, Mendel C, Spigelman M, Hermann DJ, Daily Dosing for Bedaquiline in Patients with Tuberculosis., in Antimicrob Agents Chemother, vol. 63, n. 11, 2019, DOI:10.1128/AAC.00463-19, PMC 6811417, PMID 31451504.

europa.eu

ema.europa.eu

EMA: farmaci orfani, su ema.europa.eu.
(EN) EMA: Sirturo, su ema.europa.eu. URL consultato il 15 gennaio 2021.

fda.gov

accessdata.fda.gov

(EN) Prescribing Information for Bedaquiline (PDF), su accessdata.fda.gov. URL consultato il 28 aprile 2014 (archiviato il 24 agosto 2013).

gazzettaufficiale.it

Pubblicazione sulla Gazzetta Ufficiale, su gazzettaufficiale.it.

harvard.edu

adsabs.harvard.edu

Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A, Acquired resistance of Mycobacterium tuberculosis to bedaquiline, in PLOS ONE, vol. 9, n. 7, 10 luglio 2014, pp. e102135, Bibcode:2014PLoSO...9j2135A, DOI:10.1371/journal.pone.0102135, PMC 4092087, PMID 25010492.
Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, Schulz M, Lu P, Mørtz E, McKinney JD, Andries K, Bald D, Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism, in Nature Communications, vol. 5, n. 1, febbraio 2014, p. 3369, Bibcode:2014NatCo...5.3369K, DOI:10.1038/ncomms4369, PMC 3948051, PMID 24569628.

informazionisuifarmaci.it

Bedaquilina, su informazionisuifarmaci.it. URL consultato il 14 gennaio 2021.
AIFA: Informazioni sui Farmaci, su informazionisuifarmaci.it. URL consultato il 15 gennaio 2021.

msfaccess.org

(EN) Farmaci per la prevenzione della tbc, su msfaccess.org. URL consultato il 14 gennaio 2021.

nih.gov

ncbi.nlm.nih.gov

Anil Koul, Najoua Dendouga, Karen Vergauwen, Brenda Molenberghs, Luc Vranckx, Rudy Willebrords, Zorica Ristic, Holger Lill, Ismet Dorange, Jerome Guillemont, Dirk Bald e Koen Andries, Diarylquinolines target subunit c of mycobacterial ATP synthase, in Nature Chemical Biology, vol. 3, n. 6, 2007, pp. 323-324, DOI:10.1038/nchembio884, ISSN 1552-4450 (WC · ACNP), PMID 17496888.
A. C. Haagsma, R. Abdillahi-Ibrahim, M. J. Wagner, K. Krab, K. Vergauwen, J. Guillemont, K. Andries, H. Lill, A. Koul e D. Bald, Selectivity of TMC207 towards Mycobacterial ATP Synthase Compared with That towards the Eukaryotic Homologue (PDF), in Antimicrobial Agents and Chemotherapy, vol. 53, n. 3, 2008, pp. 1290-2, DOI:10.1128/AAC.01393-08, PMC 2650532, PMID 19075053.
Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis., in Lancet Respir Med, 2017, DOI:10.1016/S2213-2600(17)30079-6, PMID 28344011.
Keam SJ, Pretomanid: First Approval., in Drugs, vol. 79, n. 16, 2019, pp. 1797-1803, DOI:10.1007/s40265-019-01207-9, PMID 31583606.
Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy CA, In search of new cures for tuberculosis (PDF), in Medicinal Chemistry, vol. 3, n. 3, maggio 2007, pp. 301-16, DOI:10.2174/157340607780620626, PMID 17504204. URL consultato il 21 gennaio 2021 (archiviato dall'url originale il 3 luglio 2020).
de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K, A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910, in Proteins, vol. 67, n. 4, giugno 2007, pp. 971-80, DOI:10.1002/prot.21376, PMID 17387738.
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Treatment of Highly Drug-Resistant Pulmonary Tuberculosis., in N Engl J Med, vol. 382, n. 10, 2020, pp. 893-902, DOI:10.1056/NEJMoa1901814, PMC 6955640, PMID 32130813.
Worley MV, Estrada SJ, Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis, in Pharmacotherapy, vol. 34, n. 11, novembre 2014, pp. 1187-97, DOI:10.1002/phar.1482, PMC 5028565, PMID 25203970.
Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A, Acquired resistance of Mycobacterium tuberculosis to bedaquiline, in PLOS ONE, vol. 9, n. 7, 10 luglio 2014, pp. e102135, Bibcode:2014PLoSO...9j2135A, DOI:10.1371/journal.pone.0102135, PMC 4092087, PMID 25010492.
Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, Schulz M, Lu P, Mørtz E, McKinney JD, Andries K, Bald D, Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism, in Nature Communications, vol. 5, n. 1, febbraio 2014, p. 3369, Bibcode:2014NatCo...5.3369K, DOI:10.1038/ncomms4369, PMC 3948051, PMID 24569628.
Healan AM, Griffiss JM, Proskin HM, O'Riordan MA, Gray WA, Salata RA, Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers., in Antimicrob Agents Chemother, vol. 62, n. 1, 2018, DOI:10.1128/AAC.00855-17, PMC 5740348, PMID 29061739.
Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F, Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB., in J Antimicrob Chemother, vol. 71, n. 4, 2016, pp. 1037-40, DOI:10.1093/jac/dkv447, PMID 26747099.
Salinger DH, Nedelman JR, Mendel C, Spigelman M, Hermann DJ, Daily Dosing for Bedaquiline in Patients with Tuberculosis., in Antimicrob Agents Chemother, vol. 63, n. 11, 2019, DOI:10.1128/AAC.00463-19, PMC 6811417, PMID 31451504.

nytimes.com

F.D.A. Approves New Tuberculosis Drug, su The New York Times, 31 dicembre 2012. URL consultato il 21 gennaio 2021.

oadoi.org

Anil Koul, Najoua Dendouga, Karen Vergauwen, Brenda Molenberghs, Luc Vranckx, Rudy Willebrords, Zorica Ristic, Holger Lill, Ismet Dorange, Jerome Guillemont, Dirk Bald e Koen Andries, Diarylquinolines target subunit c of mycobacterial ATP synthase, in Nature Chemical Biology, vol. 3, n. 6, 2007, pp. 323-324, DOI:10.1038/nchembio884, ISSN 1552-4450 (WC · ACNP), PMID 17496888.
de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K, A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910, in Proteins, vol. 67, n. 4, giugno 2007, pp. 971-80, DOI:10.1002/prot.21376, PMID 17387738.
Emanuele Pontali, Giovanni Sotgiu, Simon Tiberi, Lia D'Ambrosio, Rosella Centis e Giovanni B. Migliori, Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence, in European Respiratory Journal, vol. 50, n. 5, 2017, p. 1701462, DOI:10.1183/13993003.01462-2017, ISSN 0903-1936 (WC · ACNP).
Edward Cox e Katherine Laessig, FDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant Tuberculosis, in New England Journal of Medicine, vol. 371, n. 8, 2014, pp. 689-691, DOI:10.1056/NEJMp1314385, ISSN 0028-4793 (WC · ACNP).
Andreas H. Diacon, Alexander Pym, Martin P. Grobusch, Jorge M. de los Rios, Eduardo Gotuzzo, Irina Vasilyeva, Vaira Leimane, Koen Andries, Nyasha Bakare, Tine De Marez, Myriam Haxaire-Theeuwes, Nacer Lounis, Paul Meyvisch, Els De Paepe, Rolf P.G. van Heeswijk e Brian Dannemann, Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline, in New England Journal of Medicine, vol. 371, n. 8, 2014, pp. 723-732, DOI:10.1056/NEJMoa1313865, ISSN 0028-4793 (WC · ACNP).
Karen Cohen e Gary Maartens, A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis, in Expert Opinion on Drug Safety, vol. 18, n. 10, 2019, pp. 875-882, DOI:10.1080/14740338.2019.1648429, ISSN 1474-0338 (WC · ACNP).

researchgate.net

https://www.researchgate.net/publication/326036735_Relative_bioavailability_of_bedaquiline_tablets_suspended_in_water_Implications_for_dosing_in_children

stolaf.edu

chemapps.stolaf.edu

Formula 3D, su chemapps.stolaf.edu.

torrinomedica.it

torrinomedica.it, https://www.torrinomedica.it/schede-farmaci/sirturo_100_mg_compressa_uso_oralefl_hdpe_188_cp/#SP8 Titolo mancante per url url (aiuto). URL consultato il 20 gennaio 2021.
Scheda farmaco Torrinomedica, su torrinomedica.it. URL consultato il 15 gennaio 2021.

unibo.it

acnpsearch.unibo.it

Anil Koul, Najoua Dendouga, Karen Vergauwen, Brenda Molenberghs, Luc Vranckx, Rudy Willebrords, Zorica Ristic, Holger Lill, Ismet Dorange, Jerome Guillemont, Dirk Bald e Koen Andries, Diarylquinolines target subunit c of mycobacterial ATP synthase, in Nature Chemical Biology, vol. 3, n. 6, 2007, pp. 323-324, DOI:10.1038/nchembio884, ISSN 1552-4450 (WC · ACNP), PMID 17496888.
Emanuele Pontali, Giovanni Sotgiu, Simon Tiberi, Lia D'Ambrosio, Rosella Centis e Giovanni B. Migliori, Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence, in European Respiratory Journal, vol. 50, n. 5, 2017, p. 1701462, DOI:10.1183/13993003.01462-2017, ISSN 0903-1936 (WC · ACNP).
Edward Cox e Katherine Laessig, FDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant Tuberculosis, in New England Journal of Medicine, vol. 371, n. 8, 2014, pp. 689-691, DOI:10.1056/NEJMp1314385, ISSN 0028-4793 (WC · ACNP).
Andreas H. Diacon, Alexander Pym, Martin P. Grobusch, Jorge M. de los Rios, Eduardo Gotuzzo, Irina Vasilyeva, Vaira Leimane, Koen Andries, Nyasha Bakare, Tine De Marez, Myriam Haxaire-Theeuwes, Nacer Lounis, Paul Meyvisch, Els De Paepe, Rolf P.G. van Heeswijk e Brian Dannemann, Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline, in New England Journal of Medicine, vol. 371, n. 8, 2014, pp. 723-732, DOI:10.1056/NEJMoa1313865, ISSN 0028-4793 (WC · ACNP).
Karen Cohen e Gary Maartens, A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis, in Expert Opinion on Drug Safety, vol. 18, n. 10, 2019, pp. 875-882, DOI:10.1080/14740338.2019.1648429, ISSN 1474-0338 (WC · ACNP).

vu.nl

dare.ubvu.vu.nl

A. C. Haagsma, R. Abdillahi-Ibrahim, M. J. Wagner, K. Krab, K. Vergauwen, J. Guillemont, K. Andries, H. Lill, A. Koul e D. Bald, Selectivity of TMC207 towards Mycobacterial ATP Synthase Compared with That towards the Eukaryotic Homologue (PDF), in Antimicrobial Agents and Chemotherapy, vol. 53, n. 3, 2008, pp. 1290-2, DOI:10.1128/AAC.01393-08, PMC 2650532, PMID 19075053.

web.archive.org

Sirturo: Clinical Pharmacology, su rxlist.com. URL consultato il 28 aprile 2014 (archiviato dall'url originale il 28 febbraio 2015).
Bedaquiline, su imnotebook.com. URL consultato il 28 aprile 2014 (archiviato dall'url originale il 20 maggio 2013).
Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy CA, In search of new cures for tuberculosis (PDF), in Medicinal Chemistry, vol. 3, n. 3, maggio 2007, pp. 301-16, DOI:10.2174/157340607780620626, PMID 17504204. URL consultato il 21 gennaio 2021 (archiviato dall'url originale il 3 luglio 2020).
Bedaquiline Fumarate, su drugs.com, The American Society of Health-System Pharmacists. URL consultato l'8 dicembre 2016 (archiviato dall'url originale il 20 dicembre 2016).
(EN) Elin Svensson et al., Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children, in Br J Clin Pharmacol., vol. 84, n. 10, ottobre 2018, pp. 2384-2392, DOI:10.1111/bcp.13696. URL consultato il 14 gennaio 2021 (archiviato dall'url originale il 20 gennaio 2022).
(EN) Prescribing Information for Bedaquiline (PDF), su accessdata.fda.gov. URL consultato il 28 aprile 2014 (archiviato il 24 agosto 2013).

who.int

WHO Operational Handbook on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, su who.int, 15 giugno 2020. URL consultato il 14 gennaio 2021.

worldcat.org

Anil Koul, Najoua Dendouga, Karen Vergauwen, Brenda Molenberghs, Luc Vranckx, Rudy Willebrords, Zorica Ristic, Holger Lill, Ismet Dorange, Jerome Guillemont, Dirk Bald e Koen Andries, Diarylquinolines target subunit c of mycobacterial ATP synthase, in Nature Chemical Biology, vol. 3, n. 6, 2007, pp. 323-324, DOI:10.1038/nchembio884, ISSN 1552-4450 (WC · ACNP), PMID 17496888.
Emanuele Pontali, Giovanni Sotgiu, Simon Tiberi, Lia D'Ambrosio, Rosella Centis e Giovanni B. Migliori, Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence, in European Respiratory Journal, vol. 50, n. 5, 2017, p. 1701462, DOI:10.1183/13993003.01462-2017, ISSN 0903-1936 (WC · ACNP).
Edward Cox e Katherine Laessig, FDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant Tuberculosis, in New England Journal of Medicine, vol. 371, n. 8, 2014, pp. 689-691, DOI:10.1056/NEJMp1314385, ISSN 0028-4793 (WC · ACNP).
Andreas H. Diacon, Alexander Pym, Martin P. Grobusch, Jorge M. de los Rios, Eduardo Gotuzzo, Irina Vasilyeva, Vaira Leimane, Koen Andries, Nyasha Bakare, Tine De Marez, Myriam Haxaire-Theeuwes, Nacer Lounis, Paul Meyvisch, Els De Paepe, Rolf P.G. van Heeswijk e Brian Dannemann, Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline, in New England Journal of Medicine, vol. 371, n. 8, 2014, pp. 723-732, DOI:10.1056/NEJMoa1313865, ISSN 0028-4793 (WC · ACNP).
Karen Cohen e Gary Maartens, A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis, in Expert Opinion on Drug Safety, vol. 18, n. 10, 2019, pp. 875-882, DOI:10.1080/14740338.2019.1648429, ISSN 1474-0338 (WC · ACNP).

wsj.com

Joseph Walker e Nathalie Tadena, J&J Tuberculosis Drug Gets Fast-Track Clearance, su Wall Street Journal, 31 dicembre 2012. URL consultato il 21 gennaio 2021.